Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...
Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback